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H I G H L I G H T S
• L-DOPA-induced dyskinesia (LID) develops in many Parkinson's disease patients.
• NLX-112 is a highly selective and high efficacy serotonin 5-HT1A receptor agonist.
• In MPTP-treated marmosets NLX112 reduced LID without impairing therapeutic activity.
• NLX-112 by itself exhibited antiparkinsonian activity (decreased motor disability).
• NLX-112 is a promising drug candidate for treatment of Parkinson's disease.









A B S T R A C T
L-DOPA is the gold-standard pharmacotherapy for treatment of Parkinson's disease (PD) but can lead to the
appearance of troubling dyskinesia which are attributable to ‘false neurotransmitter’ release of dopamine by
serotonergic neurons. Reducing the activity of these neurons diminishes L-DOPA-induced dyskinesia (LID), but
there are currently no clinically approved selective, high efficacy 5-HT1A receptor agonists. Here we describe the
effects of NLX-112, a highly selective and efficacious 5-HT1A receptor agonist, on LID in 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-treated marmosets, a non-human primate model of PD.
NLX-112 exhibited modest plasma half-life (~2h) and marked plasma protein binding (96%). When ad-
ministered to parkinsonian marmosets with L-DOPA (7 mg/kg p.o.), NLX-112 (0.025, 0.1 and 0.4 mg/kg p.o.)
reduced LID scores at early time-points after administration, whilst only minimally interfering with the L-DOPA-
induced reversal of motor disability. In contrast, the prototypical 5-HT1A receptor agonist, (+)8-OH-DPAT (0.6
and 2 mg/kg p. o.), reduced LID but also abolished L-DOPA's anti-disability activity.
Administered by itself, NLX-112 (0.1, 0.2 mg/kg p.o.) produced very little dyskinesia or locomotor activity,
but reduced motor disability scores by about half the extent elicited by L-DOPA, suggesting that it may have
motor facilitation effects of its own. Both NLX-112 and (+)8-OH-DPAT induced unusual and dose-limiting
behaviors in marmoset that resembled ‘serotonin behavioral syndrome’ observed previously in rat.
Overall, the present study showed that NLX-112 has anti-LID activity at the doses tested as well as reducing
motor disability. The data suggest that additional investigation of NLX-112 is desirable to explore its potential as
a treatment for PD and PD-LID.
1. Introduction
Parkinson's disease (PD) is characterized by a loss of nigrostriatal
dopaminergic neurons resulting in the cardinal motor symptoms of
tremor, rigidity, slowness of movement, and difficulty with walking
(Schapira et al., 2006). Treatment of these motor symptoms relies
primarily on the gold-standard medication, L-3,4-dihydrox-
yphenylalanine (L-DOPA) but, over time, as the disease progresses,
more and more neurons die, and the buffering capacity of dopamine is
reduced. As a result, a sizeable proportion of patients develop dose-
limiting dyskinesia, characterized by hyperkinetic movements, in-
cluding chorea, dystonia, and athetosis (Jackson et al., 2004; Jenner
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et al., 2011; Sellnow et al., 2019). Such L-DOPA-induced dyskinesia
(LID) can become increasingly troublesome but its treatment has been
hampered by a lack of sufficiently efficacious and well-tolerated med-
ications, although some success has been achieved by use of the glu-
tamate receptor antagonist amantadine. However, its use, like that of
other glutamate NMDA receptor antagonists is limited by tolerance is-
sues and suboptimal efficacy in some patients (Pilleri and Antonini,
2015) and a clear need therefore exists for novel pharmacological ap-
proaches (Cenci et al., 2019). Over recent years, the 5-hydro-
xytryptamine (5-HT) system has emerged as a key element in the
etiology of dyskinesia. 5-HT neurons possess the enzyme necessary to
convert exogenous L-DOPA to dopamine (DA), which can be stored in
vesicles and released as a ‘false neurotransmitter’ (Carta et al., 2008;
Politis et al., 2014). However, 5-HT neurons lack appropriate control
mechanisms to regulate synaptic DA levels, resulting in excessive and
physiologically inappropriate DA release and pulsatile stimulation of
post-synaptic DA receptors that generate dyskinesia. Several lines of
evidence support this model for induction of LID, as well as the desir-
ability of a potent, selective and high efficacy 5-HT1A agonist to treat
LID: (i) destruction of serotonergic neurons with the toxin, 5,7-dihy-
droxytryptamine, leads to a near-complete suppression of LID in hemi-
parkinsonian rats (Carta et al., 2007); (ii) transplanting serotoninergic
neurons into the striatum of hemi-parkinsonian rats worsens LID
(Carlsson et al., 2007, 2009); (iii) silencing of 5-HT neurons via acti-
vation of pre-synaptic 5-HT1B or 5-HT1A autoreceptors reduces or
eliminates LID in rat and non-human primate models of LID (Carta
et al., 2007; Eskow et al., 2009; Munoz et al., 2008); (iv) the 5-HT
precursor, 5-hydroxytryptophan reduces dyskinesia in hemi-parkinso-
nian rats through displacement of DA from serotonergic vesicles and via
activation of 5-HT auto-receptors (Tronci et al., 2013).
Several attempts have been made to use serotonergic agonists, such
as buspirone, sarizotan or eltoprazine, as treatments for LID. However,
only moderate efficacy was observed, and the beneficial anti-parkin-
sonian effects of L-DOPA was reduced. The causes of these disappointing
results are likely related to several factors, including metabolic in-
stability (for buspirone) (Caccia et al., 1983; Politis et al., 2014), in-
teraction with off-target sites (notably DA D2 receptor antagonism by
sarizotan and buspirone) (Peroutka, 1985; Rabiner et al., 2002) and
lack of sufficient agonist efficacy at 5-HT1A receptors (partial agonism
by buspirone and eltoprazine). The question still remains, therefore, as
to whether a selective and high efficacy 5-HT1A receptor agonist can
show efficacious anti-LID properties without interfering with the ben-
eficial anti-parkinsonian effects of L-DOPA.
The novel 5-HT1A receptor agonist, NLX-112, fits the criteria for a
potentially superior anti-LID therapy. Unlike previous 5-HT1A receptor
agonists, NLX-112 (a.k.a. befiradol or F13640) is a potent (nanomolar
affinity), 5-HT1A receptor ‘full’ agonist and highly selective (> 1000-
fold selectivity over a wide palette of off-target sites (Colpaert et al.,
2002). NLX-112 exhibits a distinctive profile for in vitro 5-HT1A re-
ceptor activation, preferentially activating specific intracellular G-pro-
teins and signal transduction cascades. Thus, unlike 8-OH-DPAT or
buspirone, NLX-112 preferentially activates Gαo proteins and elicits
pronounced phosphorylation of ERK1/2, both in vitro and ex vivo
(Buritova et al., 2009; Newman-Tancredi et al., 2017). NLX-112 rapidly
penetrates the brain following systemic dosing (Bardin et al., 2005).
Radiolabeled 18F-NLX-112 binds specifically to rat, cat, non-human
primate (macaque) as well as human brain regions known to express 5-
HT1A receptors (Colom et al., 2020; Vidal et al., 2016, 2018). Notably,
NLX-112 efficaciously and completely inhibits the electrical activity of
dorsal raphe 5-HT neurons via activation of pre-synaptic 5-HT1A auto-
receptors (Llado-Pelfort et al., 2012). Accordingly, striatal serotonin
release is profoundly reduced by NLX-112 in 6-OH-DA-lesioned hemi-
parkinsonian rats treated with L-DOPA (Iderberg et al., 2015b). This is
accompanied by a blunting of L-DOPA-induced dopamine release,
confirming the ability of NLX-112 to inhibit serotonergic neurons re-
sponsible for the “false neurotransmitter” surge in DA release (Iderberg
et al., 2015a).
The same doses of NLX-112 that produce these neurochemical ef-
fects also abolish the electrophysiological signature (cortical slow-wave
oscillations) of LID in 6-OH-DA-lesioned rats (Brys et al., 2018) and
reverse haloperidol-induced catalepsy, a read-out of D2 receptor
blockade-induced motor impairment (Iderberg et al., 2015b). Abnormal
Involuntary Movements (AIMs) in hemi-parkinsonian rats chronically
treated with L-DOPA were dose-dependently and completely eliminated
by NLX-112 and this effect was entirely reversed by a selective 5-HT1A
receptor antagonist (Iderberg et al., 2015b). In addition, the anti-AIMs
activity of NLX-112 was maintained upon chronic treatment (14 days)
(McCreary et al., 2016a). Autoradiography studies showed that NLX-
112 dose-dependently occupies 5-HT1A receptors at doses that corre-
spond to those that are active in rat models of LID (Bardin et al., 2005).
Moreover, NLX-112 elicited marked ipsilateral rotations in hemi-par-
kinsonian rats, suggestive of motor facilitation effects (Iderberg et al.,
2015b).
Taken together, these studies show that NLX-112 has strong anti-LID
activity in rodents but the question of whether its anti-LID activity can
translate from rodent to other species remains to be investigated. A
previous study on a related compound, F15599 (a.k.a. NLX-101),
showed that it decreased LID in MPTP-treated cynomolgus macaques,
without interfering with L-DOPA's therapeutic effects (Huot et al.,
2015), suggesting that the anti-LID activity of NLX-112 would similarly
translate to primate species. The purpose of the present study was,
therefore, to test NLX-112 in a non-human primate model of LID, i.e.
MPTP-treated marmosets, which have shown high translational value to
human (Veyres et al., 2018). Prior to carrying out behavioral ob-
servations, the pharmacokinetics of NLX-112 in marmoset were in-
vestigated to determine plasma exposure at the doses tested.
2. Methods
2.1. Animals
Common marmosets (Callithrix jacchus, 5 females and 3 males, aged
8–14 years, Harlan UK Ltd. Loughborough, UK and Manchester
University, Manchester, UK), previously (6–8 years) treated with MPTP
were used for this study. They were housed alone or in pairs, in a room
maintained at constant temperature (24 ± 1 °C), 50% relative hu-
midity and with a 12-h light/dark cycle. All animals were given 1 meal
of mashed cereal and 1 meal of fresh fruit daily and had ad libitum
access to food pellets and fresh water. On behavioral test days, water
was supplied ad libitum and food was given after completion of testing.
2.2. Administration of MPTP and L-DOPA priming
Locomotor and behavioral deficits were induced by subcutaneous
administration of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
hydrochloride; Sigma Chemical, UK) 2 mg/kg daily for up to 5 con-
secutive days dissolved in sterile 0.9% saline solution (Baxter
Healthcare Ltd.). Following recovery from acute effects of MPTP-
treatment, dyskinesia was induced by chronic treatment with L-DOPA
(10–12.5 mg/kg p.o., plus benserazide (10 mg/kg po) administered up
to twice daily for up to 30 days (Pearce et al., 1995). At the start of the
study, all MPTP-treated marmosets exhibited stable motor deficits in-
cluding a marked reduction of basal locomotor activity, poor co-
ordination of movement, abnormal and/or rigid posture, reduced
alertness and head checking movements. Procedures were carried out in
accordance with the UK Animals (Scientific Procedures Act) 1986 and
with approval of the King's College London Ethical Review Panel under
project license PPL 70/8541 and were compliant with the minimal
standards as defined by the European Communities Council Directive
(85/609/EEC).
Following priming for dyskinesia expression, the animals had been
previously used for the assessment of the therapeutic and dyskinetic
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effects of other dopaminergic and non-dopaminergic agents alone and/
or in combination with L-DOPA or dopamine agonists. One animal
showed little or no dyskinesia in response to L-DOPA treatment and was
excluded from subsequent analysis. All animals received a washout of at
least 2 months prior to the start of this study. They were declared fit for
study by the named veterinary surgeon and were certificated for re-use




provided by Neurolixis and dissolved in distilled water to prepare a
stock solution and then diluted in a 10% w/v sucrose solution to pro-
vide the required dose and administered orally at a volume of 2 ml/kg.
(+)8-OH-DPAT (Tocris Cookson, Inc., Bristol, UK) was dissolved in
sterile 0.9% saline and injected s.c. at a volume of 1 ml/kg. Benserazide
HCl (Sigma, UK) was dissolved in a 10% w/v sucrose solution and
administered p.o. at a volume of 2 ml/kg. L-DOPA methyl ester HCl
(Sigma, UK) was dissolved in a 10% w/v sucrose solution. In all cases,
drug doses are expressed as the weight of the free base.
For NLX-112 plasma exposure determination, four marmosets (2 M,
2 F) received a single dose of 0.4 mg/kg p.o. For behavioral observa-
tions, the following combinations were tested: (i) L-DOPA (7 mg/kg
p.o.) in combination with NLX-112 (0.025, 0.1 and 0.4 mg/kg p.o.) or
vehicle (10% sucrose). (ii) NLX-112 (0.1 and 0.2 mg/kg p.o.) or vehicle
(10% sucrose) administered alone (i.e. in the absence of L-DOPA). (iii) L-
DOPA (7 mg/kg p.o.) given in combination with (+)8-OH-DPAT (0.6
and 2 mg/kg s.c.) or vehicle (0.9% saline). Treatments were adminis-
tered twice a week according to a modified latin square design, with a
minimum of 2 days drug free washout period between treatment days.
Benserazide was administered at t-60 min before L-DOPA, and test drug
treatment (L-DOPA, NLX-112 and (+)8-OH-DPAT) or vehicles was then
administered at time = 0 min (p.o. for L-DOPA, NLX-112; s.c. for (+)8-
OH-DPAT). Locomotor activity, motor disability and dyskinesia were
monitored before and for up to 5 h after test drug administration as
described below.
The doses of NLX-112 were based on allometric scaling, following
FDA guidelines that predict that marmoset doses should be similar to
those in rat, based on body weight and surface (FDA, 2005; Nair and
Jacob, 2016). The doses of (+)8-OH-DPAT were based on the previous
marmoset study on this compound (Iravani et al., 2006). The dose of L-
DOPA used herein (7 mg/kg p.o.) consistently triggers substantial, but
not severe, levels of LID, mimicking the clinical situation where mild-
moderate levels of LID are commonly seen. In addition, this dose of L-
DOPA produces robust (over 80% decrease) in motor disability score,
confirming its strong anti-parkinsonian-like pharmacological activity
under these conditions.
2.4. Plasma pharmacokinetics and protein binding of NLX-112 in MPTP-
treated marmosets
Following administration of NLX-112, blood was collected over a
24-h period (0, 1, 2, 4, 6 and 24 h), and plasma separated, frozen and
stored at −80 °C until analyzed. Total levels of NLX-112 were quanti-
fied in plasma by LC-MS/MS based on the method described previously
(Bardin et al., 2005). For protein binding experiments to marmoset
plasma, three concentrations of NLX-112 (100, 500 and 2500 nM) were
selected and tested in vitro using the method of equilibrium dialysis.
Briefly, the proportion of the drug able to cross a dialysis membrane
provided a measure of the ‘free’ drug concentration, detected by mi-
crodialysis.
2.5. Assessment of locomotor activity
Locomotor activity was assessed with automated activity units
(50 × 60 × 90 cm) fitted with a clear Perspex observation door and 8
horizontal photoelectric emitters/detectors (light beams). Two hor-
izontal wooden perches were fitted and drinking water was available.
Interruption of a light beam was recorded as a single locomotor count.
Animals were acclimatized individually to the activity unit for 90 min (t
−90 to t0 min), during which baseline locomotor activity was re-
corded. Subsequently, locomotor activity was recorded during serial
30 min intervals.
2.6. Assessment of motor disability and dyskinesia
Motor disability and dyskinesia were assessed simultaneously in the
automated activity units at 20 or 30 min intervals (see figures for de-
tails). For each scoring period the animals were observed for the last
10 min of the period (e.g. for the first 30 min period, the animals were
observed from 20 to 30 min). The lowest motor disability and the
greatest dyskinesia scores were recorded for each period. The assess-
ment of motor disability was performed with an established rating
scale: alertness (normal = 0, reduced = 1, sleepy = 2); checking
(present = 0, reduced = 1, absent = 2); posture (normal = 0, ab-
normal trunk +1, abnormal tail + 1, abnormal limbs + 1, flexed = 4);
balance (normal = 0, impaired = 1, unstable = 2, spontaneous
falls = 3); reaction to stimuli (normal = 0, reduced = 1, slow = 2,
absent = 3); vocalization (normal = 0, reduced = 1, absent = 2);
motility (normal = 0, bradykinesia = 1, akinesia = 2). These values
were summed, a maximum score of 18 indicating severe motor dis-
ability, a minimum score of 0 indicating normal motor behavior.
Assessment of dyskinesia was performed with an established rating
scale: 0 = absent; 1 = mild, fleeting and rare dyskinetic postures and
movements; 2 = moderate: more prominent abnormal movements, but
not significantly affecting normal behavior; 3 = marked, frequent and
at times continuous dyskinesia affecting the normal pattern of activity;
4 = severe, virtually continuous dyskinetic activity, disabling to the
animal and replacing normal behavior.
The assessment of motor disability and dyskinesia was performed by
an observer blinded to the treatment.
2.7. Statistical and data analysis
Data for the plasma level determination experiment are presented as
the mean of duplicate measures. Data for dyskinesia and motor dis-
ability being ordinal in nature, are presented graphically as median
values at each time point. They were then subjected to a square root
transformation [y = sqrt(y)] to make them amenable to parametric one
or two-way ANOVA (see below). Data for locomotor activity are pre-
sented graphically as mean values at each time point. Data for the ef-
fects of NLX-112 (when administered alone) were analyzed with a one-
way ANOVA for repeated measures with time as the within-subjects
factor. Data for the combination of NLX-112 and L-DOPA were analyzed
with a two-way ANOVA, with treatment and time as the within-subjects
factors. Where applicable, ANOVAs were followed by Dunnett's post-
hoc tests for comparison with the −60 min time point (one-way
ANOVA) or with the L-DOPA alone group as the control, for each time
point (two-way ANOVA).
3. Results
3.1. Plasma levels and protein binding of NLX-112 in MPTP-treated
marmosets
In 3 out of 4 animals tested (2 M, 2 F), peak plasma exposure of
NLX-112 occurred at 1-h post dosing with levels between 130 and
370 ng/ml (Fig. 1). For animal PX34, exposure was higher and more
sustained over 4 h post-dosing. NLX-112 was fairly rapidly eliminated
such that, in 3 out of 4 animals, plasma levels at 6 h were around 10 ng/
ml. Although the numbers of animals in this study is too small to draw
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firm conclusions, it is noted that the two male marmosets exhibited
higher exposure levels than the two females. The data suggests that
plasma half-life in marmoset is about 2 h.
As concerns plasma protein binding, the percentage of unbound
NLX-112 was independent of initial concentration in all cases. The
unbound fraction of NLX-112 was 3.8–4.5%, giving a plasma protein
binding (PPB) value of 96%.
3.2. Effects of NLX-112 on L-DOPA-induced effects
3.2.1. Dyskinesia score
L-DOPA, by itself, increased dyskinesia scores, with peak median
values of 3 at 90 and 120 min post treatment (open squares, Fig. 2, top
panel). NLX-112 attenuated dyskinesia scores, reducing median values
to 2 or less at doses of 0.1 and 0.4 mg/kg. There was a significant time
effect [F (12,72) = 14.22; P < 0.0001] and treatment × time inter-
action [F (36,216) = 1.77; P < 0.01, but not treatment effect [F
(3,18) = 0.68; ns]]. Subsequent post-hoc analysis showed that NLX-112
significantly reduced dyskinesia scores by around 50% at various time x
dose combinations between 30 and 120 min (see statistical symbols in
top panel Fig. 2).
Compared to the score observed before drug administration (t
−60 min), NLX-112 alone (0.4 mg/kg) significantly [F (12,72) = 3.20;
P < 0.01] modified the dyskinesia score at 30 min with 3 out of 7
animals showing fleeting bouts of dyskinesia. Note: this is not re-
presented graphically as the figure (inset, Fig. 2) shows median values,
whereas the statistical analysis was done on square-root transformed
raw score.
3.2.2. Motor disability score
Administered alone, L-DOPA decreased motor disability score in the
period from 30 to 180 min, with a slow return to pre L-DOPA levels
from 180 min onward (open squares, Fig. 2, middle panel). NLX-112
did not significantly modify the beneficial effects of L-DOPA, i.e. did not
interfere with the decrease in disability score (treatment factor: [F
Fig. 1. Plasma Levels of NLX-112 in Marmosets. Symbols represent the mean of
duplicate measures taken from the same plasma sample following administra-
tion of 0.4 mg/kg p.o. NLX-112 was quantified by LC-MS/MS. The same data
are plotted on a linear scale y-axis (upper panel) and on a log10 scale y-axis
(lower panel). M: male, F: female.
Fig. 2. Time course of effects of NLX-112 in combination with L-DOPA (main
panels) or alone (insets). Main panels: NLX-112 or vehicle and L-DOPA (7 mg/
kg) were administered p.o. at t = 0 min (arrows). Benserazide was adminis-
tered at t = −60 min. For dyskinesia and motor disability, data are presented
as median values and were analyzed by two-way ANOVA on transformed data
[y = sqrt(y)]. For locomotor activity, data are presented as mean values, and
were analyzed by two-way ANOVA on raw data. *p < 0.05, **p < 0.01,
versus L-DOPA alone at the considered time point, Dunnett's post-hoc tests.
N = 7 per group. Insets: NLX-112 was administered alone p.o. at t = 0 min
(arrows). For dyskinesia and motor disability, data are presented as median
values and were analyzed by one-way ANOVA on transformed data [y = sqrt
(y)]. For locomotor activity, data are presented as mean values, and were
analyzed by one-way ANOVA on raw data. *p < 0.05, **p < 0.01 versus
value at t = −60 min (dyskinesia and motor disability) or t = −90 min (lo-
comotor activity), Dunnett's post-hoc tests.
R. Fisher, et al. Neuropharmacology 167 (2020) 107997
4
(3,18) = 2.70, ns], treatment × time interaction [F (36,216) = 1.19;
ns], but significant time effect [F (12,72) = 52.17; P < 0.0001]). On
its own, NLX-112 significantly decreased the motor disability score [F
(12, 72) = 2.92, P < 0.01, inset], most prominently at 30 min, but
also at 180 and 210 min post-treatment.
3.2.3. Locomotor activity
Administration of L-DOPA stimulated locomotor activity, with peak
effect recorded between 180 and 240 min (open squares, Fig. 2, bottom
panel). NLX-112 significantly attenuated this hyperlocomotor activity,
most prominently from 60 to 120 min post-administration. There was a
significant treatment × time interaction effect [F (39,234) = 1.85;
P < 0.01] and time effect [F (13,78) = 7.31; P < 0.0001, but not
treatment effect [F (3, 18) = 0.64; ns]. By itself, NLX-112 very mod-
estly increased locomotor activity [F (13, 78) = 4.57; P < 0.0001],
with a significant increase observed only at 30 min post-treatment
(Fig. 2, bottom panel, inset).
3.2.4. Induction of unusual behaviors by NLX-112
At 0.1 and 0.4 mg/kg, NLX-112 in combination with L-DOPA pro-
duced mainly dystonia and scratching, most prominently at the 0.4 mg/
kg dose. Sedation-like, dystonia and scratching behaviours were also
observed with NLX-112 alone at 0.4 mg/kg (Supplementary Table).
3.3. Effects of NLX-112 alone
3.3.1. Dyskinesia score
Vehicle-treated marmosets presented no observable dyskinesia
during the observation period (open diamonds, Fig. 3, top panel). NLX-
112 slightly increased dyskinesia scores, with peak effect (median value
of 1) observed for each dose at some time points. Statistical analysis
revealed that there was a significant time effect [F (15, 105) = 4.56;
P < 0.0001], treatment effect [F (2, 14) = 5.33; P < 0.05] and
treatment × time interaction [F (30, 210) = 2.19; P < 0.001]. The
peak dyskinesia scores reflect occasional mild and fleeting dyskinetic
postures and movements.
3.3.2. Motor disability score
Following administration of vehicle, marmosets presented a stable
and high level of motor disability (median scores fluctuating between 9
and 12 over the whole observation period: Fig. 3, middle panel). NLX-
112 significantly lowered the disability score (treatment effect: [F (2,
14) = 6.64; p < 0.01]; time effect: [F (15, 105) = 8.73; P < 0.0001]
and treatment × time interaction [F (30, 210) = 1.88; P < 0.01]),
with median scores being reduced to 4.5–5 at most time points from 20
to 160 min post-treatment.
3.3.3. Locomotor activity
Administration of vehicle had no effect on locomotor activity
(Fig. 3, bottom panel). NLX-112 produced a small but significant aug-
mentation of locomotor activity, most notably at the lower dose tested,
at various time points, with peak effects around 200% above those of
vehicle values [treatment effect: F (2, 14) = 8.08; P < 0.01, time
effect: F (13, 91) = 3.80, P < 0.0001 and treatment × time inter-
action: F (26, 182) = 2.21, P < 0.01.
3.4. Effects of (+)8-OH-DPAT on L-DOPA-induced effects
3.4.1. Dyskinesia score
L-DOPA by itself produced a time-dependent increase in the dyski-
nesia score, with median peak values of 2 from 30 to 90 min post-
treatment (open symbols, Fig. 4, top panel). In combination with L-
DOPA, (+)8-OH-DPAT at both doses reduced dyskinesia (non sig-
nificant treatment effect [F (2,12) = 0.15; ns], but significant time
effect [F (12, 72) = 5.64; P < 0.0001] and treatment × time inter-
action [F (24,144) = 1.79; P < 0.05]. Subsequent post-hoc analysis
showed that (+)8-OH-DPAT significantly reduced dyskinesia scores at
both doses from 30 to 90 min post-treatment. By itself, (+)8-OH-DPAT,
at 2 mg/kg s.c., produced no dyskinesia (inset; treatment effect [F
(12,72) = 1.47; ns]).
3.4.2. Motor disability score
Administered alone, L-DOPA decreased motor disability from 30 to
210 min, with a return to pre-treatment levels from 210 min onward
(open squares, Fig. 4, middle panel). When co-administered with L-
DOPA, (+)8-OH-DPAT attenuated the anti-disability effect of L-DOPA
(treatment factor: [F (2, 12) = 10.17; p < 0.01], with significant time
effect [F (12, 72) = 5.46; P < 0.0001] and treatment × time inter-
action [F (24, 144) = 5.73; P < 0.0001]. Post-hoc analysis detected
increased motor disability scores at most time points from 30 to
210 min post-treatment, compared to L-DOPA alone. (+)8-OH-DPAT,
administered alone, significantly increased the disability score (treat-
ment factor: [F (12, 72) = 1.94; p < 0.05]; however, post-hoc analysis
detected no time at which it was significantly different to pretreatment
levels (inset).
Fig. 3. Time course of the effects of NLX-112 alone. NLX-112 or vehicle were
administered at t = 0 min; benserazide was administered at t = −60 min. For
dyskinesia and motor disability, data are presented as median values and were
analyzed by two-way ANOVA on transformed data [y = sqrt(y)]. For locomotor
activity, data are presented as mean values, and were analyzed by two-way
ANOVA on raw data. *p < 0.05, **p < 0.01, versus vehicle at the considered
time point, Dunnett's post-hoc tests. N = 7 per group.
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3.4.3. Locomotor activity
Administration of L-DOPA stimulated locomotor activity, with peak
effect recorded at 90 min (open squares, Fig. 4, bottom panel). In
combination with L-DOPA, (+)8-OH-DPAT attenuated this locomotor
enhancement (non significant treatment effect [F (2, 12) = 1.37; ns],
but significant time [F (13, 78) = 2.80, P < 0.01] and treat-
ment × time interaction [F (26, 156) = 2.73, P < 0.0001]. Post-hoc
analysis showed that (+)8-OH-DPAT decreased locomotion as com-
pared to L-DOPA alone mostly at 0.06 mg/kg from 60 to 120 min post-
treatment. (+)8-OH-DPAT had no effect on locomotor activity as
compared to pre-treatment values (inset, Fig. 4 bottom panel; treatment
effect [F (13, 78) = 0.86; ns]).
3.4.4. Induction of unusual behaviors by (+)8-OH-DPAT
At 0.6 and 2 mg/kg s.c., (+)8-OH-DPAT in combination with L-
DOPA produced various behavioral effects, including dystonia and se-
dation-like behavior, most prominently at the 2 mg/kg dose. Severe
dystonia and flat body posture were also observed when (+)8-OH-
DPAT was administered alone at 2 mg/kg (Supplementary Table).
4. Discussion
NLX-112 (a.k.a. befiradol or F13640), is a centrally acting, highly
efficacious and highly selective 5-HT1A receptor agonist being devel-
oped for the treatment of LID in PD. Although it has been extensively
tested in multiple models in rodent species, including electro-
physiology, microdialysis, behavior and brain imaging (Brys et al.,
2018; Iderberg et al., 2015b; McCreary et al., 2016a; Newman-Tancredi
et al., 2018a,b; Vidal et al., 2018), this is the first report of its effects in
the MPTP-treated marmoset model of PD. The principal findings are as
follows: (i) The duration of plasma exposure of NLX-112 in marmosets
was relatively modest, which may limit its pharmacological effects in
this species. (ii) NLX-112 exhibited moderate but potent dose-depen-
dent anti-dyskinetic activity in L-DOPA-treated parkinsonian marmosets
(effects notably at 0.4 mg/kg p.o.). (iii) NLX-112 only marginally in-
terfered with the anti-parkinsonian effects of L-DOPA, unlike reference
5-HT1A receptor agonist, (+)8-OH-DPAT, which reduced LID but also
abolished the anti-parkinsonian effects of L-DOPA. (iv) NLX-112 alone
exhibited anti-parkinsonian-like activity in parkinsonian marmosets.
(v) Both NLX-112 and (+)8-OH-DPAT produced serotonergic beha-
vioral effects in marmosets, which were dose-limiting and interfered
with some behavioral observations. Such motor effects were not pre-
viously observed in another NHP species, cynomolgous macaques
(Macaca fascicularis) at doses equivalent to or even higher than those
used here, or in previous clinical trials with NLX-112, suggesting that
marmosets are particularly sensitive to serotonergic activation. These
findings are discussed in more detail below.
4.1. Contrasting effects of NLX-112 and (+)8-OH-DPAT on L-DOPA-
induced behaviors
NLX-112 elicited anti-dyskinetic activity in parkinsonian marmosets
at specific time-points following drug administration. The lower doses
(0.025 and 0.1 mg/kg p.o.) reduced dyskinesia scores at a couple of
time points, but the higher dose (0.4 mg/kg p.o.) elicited significant
effects at most time points between 30 and 120 min post-treatment
(Fig. 2). The median dyskinesia scores for the 0.4 mg/kg p.o. dose were
reduced from 2 or 3 down to 1 or zero at all time-points, indicating a
reduction from troublesome to non-troublesome dyskinesia. One factor
that may influence the extent and duration of the anti-LID activity of
NLX-112 is the relatively short half-life of NLX-112 plasma exposure in
marmoset (Fig. 1). Indeed, NLX-112 exposure in 3 out of 4 animals was
strongly reduced within 2 h of administration, a profile which more
closely resembles that of rats (around 1–2 h (Bardin et al., 2005)) than
that of human subjects (> 20 h) (Paillard et al., 2016).
A marked inter-individual variability in LID scores was observed,
suggesting that a larger cohort of marmosets might have increased
statistical resolution, particularly at early time-points when NLX-112
exposure was highest. NLX-112 also elicited unusual behaviors which
resembled serotonergic behavioral syndrome. This might have con-
founded scoring of LID, in addition to preventing higher (and poten-
tially more active) doses from being tested (see additional discussion on
this point below). Nevertheless, despite these limitations, the present
data are consistent with significant oral anti-LID activity of NLX-112.
They also extend to marmoset the observations previously reported in
hemi-parkinsonian rat where NLX-112 abolished L-DOPA-induced AIMs
(Iderberg et al., 2015b), and retained this activity upon 14-day repeated
administration (McCreary et al., 2016a).
Notably, NLX-112 did not markedly interfere with the anti-disability
Fig. 4. Time course of effects of (+)8-OH-DPAT alone or in combination with L-
DOPA. Main panels: (+)8-OH-DPAT (8-OH) and its vehicle were administered
i. p. and L-DOPA (7 mg/kg) was administered p. o. at t = 0 min (arrows).
Benserazide was administered at t = −60 min. For dyskinesia and motor
disability, data are presented as median values and were analyzed by two-way
ANOVA on transformed data [y = sqrt(y)]. For locomotor activity, data are
presented as mean values, and were analyzed by two-way ANOVA on raw data.
*p < 0.05, **p < 0.01, versus L-DOPA alone at the considered time point,
Dunnett's post-hoc tests. N = 7 per group. Insets: (+)8-OH-DPAT was ad-
ministered alone i. p. at t = 0 min (arrows). For dyskinesia and motor dis-
ability, data are presented as median values and were analyzed by one-way
ANOVA on transformed data [y = sqrt(y)]. For locomotor activity, data are
presented as mean values, and were analyzed by one-way ANOVA on raw data.
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effects of L-DOPA. The latter strongly reduced parkinsonism scores of
MPTP-treated marmosets (median values decreased from about 12 to
2–3) and NLX-112 only slightly opposed this effect at a single time-
point at the highest dose (0.4 mg/kg p.o., Fig. 2). This sharply distin-
guishes NLX-112 from the prototypical 5-HT1A receptor agonist (+)8-
OH-DPAT (Huot, 2018). The latter was tested herein at the same doses
as previously reported (i.e. 0.6 and 2.0 mg/kg p.o.) (Iravani et al.,
2006), and reduced dyskinesia elicited by L-DOPA (Fig. 4, top). How-
ever, whereas L-DOPA produced a strong decrease in mean motor dis-
ability scores, from 12 to about 2–5 (Fig. 4 middle), (+)8-OH-DPAT
completely abolished this therapeutic-like effect (Fig. 4 middle). This
observation is in accordance with a previous studies of the effects of
(+)8-OH-DPAT (Iravani et al., 2006) and of other 5-HT1A receptor
agonists which also found that reduction of dyskinesia was accom-
panied by loss of anti-disability effects (Bezard et al., 2013; Gregoire
et al., 2009; Iravani et al., 2006). NLX-112 therefore exhibits a dis-
tinctive pattern of activity, attenuating LID in parkinsonian marmosets,
but with minimal effects on L-DOPA-induced therapeutic-like properties
on motor disability. In addition, in a recent study, NLX-112 also elicited
robust anti-LID properties (without impacting L-DOPA anti-parkinso-
nian activity) in a second non-human primate species, MPTP-treated
cynomolgus macaques, over a dose-range similar to the one used herein
(0.03–0.3 mg/kg p.o.) (Johnston et al.; manuscript in preparation).
4.2. Anti-parkinsonian-like effects of NLX-112
In addition to attenuating LID, NLX-112, by itself, also reduced
parkinsonism behavior. Vehicle-treated marmosets had motor disability
scores of 10–12 and these were reduced to about 5–6 by low doses of
NLX-112 (0.1 and 0.2 mg/kg p.o.; Fig. 3, middle panels). Interestingly,
the higher dose of NLX-112 (0.4 mg/kg p.o.) appeared less active than
the lower doses, only reducing disability at a single early time-point
(compare Fig. 3 middle panel with inset of Fig. 2 middle panel), sug-
gesting an inverted dose-response relationship. To our knowledge, this
is the first time that such anti-parkinsonian effects have been observed
in NHP for a 5-HT1A receptor agonist. An indication that NLX-112 may
possess a motor facilitation activity was seen in hemi-parkinsonian rats,
in which NLX-112 stimulated rotation behavior, a response associated
with anti-parkinsonian effects (Iderberg et al., 2015b). The underlying
mechanism for that activity was not established, but may involve direct
activation of 5-HT1A receptor subpopulations in basal ganglia. Indeed,
brain imaging studies using 18F-labelled NLX-112 in rat, cat and NHP
have identified binding sites in caudate/striatum which may be func-
tionally active (Vidal et al., 2018). NLX-112 also elicits a specific glu-
cose uptake (18F-fluorodeoxyglucose PET labelling) pattern in rat cor-
tical and subcortical areas (Levigoureux et al., 2019b) and ongoing
human brain imaging will determine if these brain regions are labelled
in human brain (Colom et al., 2020). In any case, the effects of NLX-112
contrast strongly with those of (+)8-OH-DPAT (Fig. 4) (Iravani et al.,
2006). The latter showed no anti-parkinsonian activity by itself but, on
the contrary, increased motor disability at a low dose of 0.6 mg/kg
(Iravani et al., 2006) (see discussion below). This is consistent with the
diversity in the effects of 5-HT1A receptor agonists that has been also
observed in rat: (+)8-OH-DPAT and another agonist, tandospirone,
both exhibit anti-AIMs effects in rats (Bishop et al., 2009; Iderberg
et al., 2015a) but elicited contralateral rotation in 6-OH-DA-lesioned
hemi-parkinsonian rats (Gerber et al., 1988; Iderberg et al., 2015a;
Matsubara et al., 2006) whereas NLX-112 produces ipsilateral rotations
(Iderberg et al., 2015b). Overall, these observations indicate that dif-
ferent 5-HT1A receptor agonists can elicit divergent effects on motor
control in both rodent and NHP models of PD. In particular, the data
suggest that NLX-112 may have therapeutic activity against the primary
motor symptoms of PD as well as reducing LID. Nevertheless, caution is
warranted as to the translatability of anti-parkinsonian effects from
marmoset to human, and further investigation is necessary to under-
stand the exact mechanisms underlying such differences – see
discussion below.
4.3. Mechanisms underlying the distinctive profile of NLX-112 in MPTP-
treated marmosets
The neurological mechanisms underlying the properties of NLX-112
remain to be fully elucidated. At a molecular level, NLX-112 pre-
ferentially activates Gαo proteins and ERK1/2 phosphorylation via 5-
HT1A receptors, a characteristic that differentiates it from other 5-HT1A
receptor agonists, including (+)8-OH-DPAT (Buritova et al., 2009;
Newman-Tancredi et al., 2017). It may, therefore, be speculated that
NLX-112 more specifically activates 5-HT1A receptor signal transduc-
tion pathways associated with brain regions controlling motor re-
sponses. At a neurochemical level, anti-dyskinetic activity is most likely
related to inhibition of serotonergic projections from the raphe nuclei to
the basal ganglia, which would blunt ‘false neurotransmitter’ DA re-
lease. Strong support for this mechanism has been generated in rodent
models (see Introduction), and imaging data in human also supports
this interpretation (Politis et al., 2014; Roussakis et al., 2016). NLX-112
has some ‘biased agonism’ for activation of 5-HT1A autoreceptors
(Buritova et al., 2009) but other mechanisms may be involved, such as a
direct effect of NLX-112 in striatal regions. This is suggested by the fact
that local administration of 5-HT1A receptor agonists (including (± )8-
OH-DPAT and F13714, a close chemical analogue of NLX-112) in rat
striatum elicited efficacious anti-dyskinetic activity in rats, pointing to
the presence of active populations of 5-HT1A receptors in that brain
region (Bishop et al., 2009; Meadows et al., 2017). Moreover, PET
imaging of 5-HT1A receptors in marmoset brain using 18F–F13714
showed labelling in subcortical areas and raphe nuclei (Yokoyama
et al., 2016), as expected, but also in caudate nucleus and putamen
(Yokoyama et al., 2016). Subsequent PET imaging using 18F-NLX-112 in
rat, cat and Rhesus macaques (Macaca mulatta) found pronounced la-
beling in thalamus and dorsal raphe (Vidal et al., 2018). An ongoing
clinical PET imaging investigation with 18F-NLX-112 is expected to shed
light on whether such patterns of labelling are also observed in healthy
human subjects (Colom et al., 2020). Ultimately, it will be interesting to
determine whether NLX-112 differentially activates 5-HT1A receptors in
patients with Parkinson's disease compared with healthy controls. In-
itial preclinical investigation of this issue using hemi-parkinsonian (6-
OH-DA-lesioned) rats suggests that induction of dyskinesia is associated
with decreased 5-HT1A receptor expression in sub-cortical regions and
increased sensitivity to agonist stimulation (Levigoureux et al., 2019a).
4.4. Serotonergic effects of NLX-112 and (+)8-OH-DPAT
NLX-112 (0.1–0.4, but not 0.025 mg/kg p.o.), administered acutely,
produced dose-dependent unusual behaviors in the marmosets, in-
cluding sedation, scratching, wet dog shakes and dystonia in the tail.
Similar effects were observed upon administration of the reference 5-
HT1A receptor agonist, (+)8-OH-DPAT. Although a formal scoring
system for such behaviors in marmoset has not been described, these
signs are reminiscent of the ‘serotonergic behavioral syndrome’ ob-
served in rat, including forepaw treading, flat body posture, Straub tail
and slowed behavior (Aubert et al., 2012; Iderberg et al., 2015b; Smith
and Peroutka, 1986). This suggests that the behaviors result from
common neurobiological mechanisms i.e. activation of 5-HT1A re-
ceptors, thus providing evidence that the compounds do engage the
intended receptor target. However, these behaviors became dose-lim-
iting: higher doses of NLX-112 could, potentially, have been more ef-
fiacious in reducing LID. It should be noted that, in rats, repeated or
continuous treatment with NLX-112, or other 5-HT1A receptor agonists
elicits tachyphylaxis to this serotonergic behavioral syndrome (Iderberg
et al., 2015b; Prinssen et al., 2000). This is in contrast to the anti-AIMs
effects of NLX-112, where tachyphylaxis is not seen and effects are
maintained over chronic administration (McCreary et al., 2016b). Ser-
otonergic behavioral syndrome in rat has been suggested to imply
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potential side effects at a clinical level (Lindenbach et al., 2015).
However, in the study of NLX-112 in MPTP-treated cynomolgus ma-
caques mentioned above, NLX-112 did not elicit movements or beha-
viours that could be classified as “serotonergic behavioral syndrome”
up to 0.3 mg/kg p.o. (Johnston et al.; manuscript in preparation). It is
also interesting that when F15599, a close chemical analogue of NLX-
112, was tested in MPTP-treated parkinsonian cynomolgus macaques,
no “serotonergic behavioral syndrome” effects were observed in that
species (Huot et al., 2015). Moreover, NLX-112 previously underwent
regulatory 3-month toxicology studies in cynomolgus macaques and did
not induce “serotonergic behavioral syndrome” (with a dose titration
from 0.025 to 2 mg/kg bid p.o. over 14 days: Neurolixis data on file).
Finally, when NLX-112 was tested previously in clinical trials (ad-
ministered to over 500 subjects for non-PD indications in clinical trials
lasting up to 2 months), side-effects consisted principally of nausea and
dizziness, but motor side-effects were not observed (unpublished ob-
servations and (Paillard et al., 2016)). Taken together, these observa-
tions suggest that marmosets may be a species that is particularly
sensitive to “serotonergic behavioral syndrome” and that the latter,
unlike the anti-dyskinetic effects of 5-HT1A receptor activation, does not
translate to other NHP species or to human. It should be noted that 5-
HT1A receptor activation is also associated with other, potentially
beneficial, properties. Indeed, NLX-112 exhibits potent antidepressant-
like activity (Iderberg et al., 2015b) in rodent behavioral tests and in-
creases extracellular DA concentrations in the medial prefrontal cortex
(Llado-Pelfort et al., 2012), consistent with activity against mood def-
icits. Moreover, NLX-112 is potently active in a range of rat pain models
(Colpaert, 2006), suggesting possible utility against the chronic pain
symptoms experienced by many PD patients (Rana et al., 2013, 2016).
However, the extent to which such beneficial serotonergic properties
are expressed in a clinical setting remains to be determined.
5. Conclusions
The present observations indicate that NLX-112 has anti-dyskinetic
activity in MPTP-treated marmosets at the doses tested. This is con-
sistent with prior observations in hemi-parkinsonian rats and, im-
portantly, NLX-112 exerted only very slight interference with the anti-
parkinsonian effects of L-DOPA, unlike reference 5-HT1A receptor ago-
nist, (+)8-OH-DPAT, which completely suppressed the effects of L-
DOPA. The present data therefore further highlight the distinctive
profile of NLX-112 in comparison with other serotonergic compounds.
Nevertheless, the magnitude of the anti-LID effects in marmoset was
likely limited by the rather short plasma half-life of the compound in
this species and by the dose-limiting induction of the “serotonergic
behavioral syndrome” – such effects were not seen with NLX-112 in
other non-human primate species (Cynomolgus or Rhesus macaques) or
in human. In addition to anti-LID activity, NLX-112 also exhibited anti-
motor disability activity on its own in the MPTP-treated marmosets. To
our knowledge, this is the first observation of such activity for a 5-HT1A
receptor agonist in an NHP species. Such activity is intriguing and
suggests that NLX-112 could attenuate parkinsonian symptoms in some
patients and/or have some L-DOPA dose-sparing activity. Nevertheless,
such interpretations require further investigation, preferably in a clin-
ical setting. In conclusion, in view of the accumulated molecular,
neurochemical and behavioral data pointing to efficacious and potent
activity of NLX-112, it would be desirable to conduct appropriately-
designed clinical trials to determine its utility as a pharmacotherapeutic
for patients suffering from Parkinson's disease or, potentially, other
movement disorders.
Declaration of competing interest
AN-T, MAV and RD are employees and/or stockholders of Neurolixis
Inc. The other authors have no disclosures.
Acknowledgements
Funding for the study was provided by Parkinson's UK Foundation.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neuropharm.2020.107997.
References
Aubert, Y., Gustison, M.L., Gardner, L.A., Bohl, M.A., Lange, J.R., Allers, K.A., Sommer,
B., Datson, N.A., Abbott, D.H., 2012. Flibanserin and 8-OH-DPAT implicate serotonin
in association between female marmoset monkey sexual behavior and changes in
pair-bond quality. J. Sex. Med. 9 (3), 694–707. https://doi.org/10.1111/j.1743-
6109.2011.02616. PMID: 22304661.
Bardin, L., Assie, M.B., Pelissou, M., Royer-Urios, I., Newman-Tancredi, A., Ribet, J.P.,
Sautel, F., Koek, W., Colpaert, F.C., 2005. Dual, hyperalgesic, and analgesic effects of
the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-
fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-am ino]-methyl}piper-
idin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occu-
pancy and kinetic parameters. J. Pharmacol. Exp. Therapeut. 312 (3), 1034–1042.
https://doi.org/10.1124/jpet.104.077669. PMID: 15528450.
Bezard, E., Tronci, E., Pioli, E.Y., Li, Q., Porras, G., Bjorklund, A., Carta, M., 2013. Study
of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced
dyskinesia. Movement disorders. Mov Disord 28 (8), 1088–1096. https://doi.org/10.
1002/mds.25366. PMID: 23389842.
Bishop, C., Krolewski, D.M., Eskow, K.L., Barnum, C.J., Dupre, K.B., Deak, T., Walker,
P.D., 2009. Contribution of the striatum to the effects of 5-HT1A receptor stimulation
in L-DOPA-treated hemiparkinsonian rats. J. Neurosci. Res. 87 (7), 1645–1658.
https://doi.org/10.1002/jnr.21978. PMID: 19115412.
Brys, I., Halje, P., Scheffer-Teixeira, R., Varney, M., Newman-Tancredi, A., Petersson, P.,
2018. Neurophysiological effects in cortico-basal ganglia-thalamic circuits of anti-
dyskinetic treatment with 5-HT1A receptor biased agonists. Exp. Neurol. 302,
155–168. https://doi.org/10.1016/j.expneurol.2018.01.010. PMID: 29339052.
Buritova, J., Berrichon, G., Cathala, C., Colpaert, F., Cussac, D., 2009. Region-specific
changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2
phosphorylation in rat brain: a quantitative ELISA study. Neuropharmacology 56 (2),
350–361. https://doi.org/10.1016/j.neuropharm.2008.09.004. PMID: 18809418.
Caccia, S., Muglia, M., Mancinelli, A., Garattini, S., 1983. Disposition and metabolism of
buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotica 13
(3), 147–153. https://doi.org/10.3109/00498258309052248. PMID: 6613160.
Carlsson, T., Carta, M., Munoz, A., Mattsson, B., Winkler, C., Kirik, D., Bjorklund, A.,
2009. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-
induced dyskinesias in parkinsonian rats is determined by the extent of dopamine
neuron degeneration. Brain: J. Neurol. 132 (Pt 2), 319–335. https://doi.org/10.
1093/brain/awn305. PMID: 19039008.
Carlsson, T., Carta, M., Winkler, C., Bjorklund, A., Kirik, D., 2007. Serotonin neuron
transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson’s
disease. J. Neurosci. : the official journal of the Society for Neuroscience 27 (30),
8011–8022. https://doi.org/10.1523/JNEUROSCI.2079-07.2007. PMID: 17652591.
Carta, M., Carlsson, T., Kirik, D., Bjorklund, A., 2007. Dopamine released from 5-HT
terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain: J.
Neurol. 130 (pt 7), 1819–1833. https://doi.org/10.1093/brain/awm082. PMID:
17452372.
Carta, M., Carlsson, T., Munoz, A., Kirik, D., Bjorklund, A., 2008. Serotonin-dopamine
interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog.
Brain Res. 172, 465–478. https://doi.org/10.1016/S0079-6123(08)00922-9. PMID:
18772046.
Cenci, M.A., Riggare, S., Pahwa, R., Eidelberg, D., Hauser, R.A., 2019. Dyskinesia matters.
Mov. Disord. https://doi.org/10.1002/mds.27959. PMID: 31872501.
Colom, M., Costes, N., Redoute, J., Dailler, F., Gobert, F., Le Bars, D., Billard, T., Newman-
Tancredi, A., Zimmer, L., 2020. 18F-F13640 PET imaging of functional receptors in
humans. Eur. J. Nucl. Med. Mol. Imag. 47 (1), 220–221. https://doi.org/10.1007/
s00259-019-04473-7. PMID: 31414208.
Colpaert, F.C., 2006. 5-HT1A receptor activation: new molecular and neuroadaptive me-
chanisms of pain relief. Curr. Opin. Invest. Drugs 7, 40–47 PMID: 16425670.
Colpaert, F.C., Tarayre, J.P., Koek, W., Pauwels, P.J., Bardin, L., Xu, X.J., Wiesenfeld-
Hallin, Z., Cosi, C., Carilla-Durand, E., Assie, M.B., Vacher, B., 2002. Large-amplitude
5-HT1A receptor activation: a new mechanism of profound, central analgesia.
Neuropharmacology 43 (6), 945–958. https://doi.org/10.1016/s0028-3908(02)
00119-3. PMID: 12423664.
Eskow, K.L., Dupre, K.B., Barnum, C.J., Dickinson, S.O., Park, J.Y., Bishop, C., 2009. The
role of the dorsal raphe nucleus in the development, expression, and treatment of L-
dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63, 610–620. https://
doi.org/10.1002/syn.20630. PMC2741636.
FDA, 2005. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial
Clinical Trials for Therapeutics in Adult Healthy Volunteers. In: (CDER), C.f.D.E.a.R.
(Ed.), U.S. Department of Health and Human Services, Food and Drug Administration
(FDA).
Gerber, R., Altar, C.A., Liebman, J.M., 1988. Rotational behavior induced by 8-hydroxy-
DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats.
R. Fisher, et al. Neuropharmacology 167 (2020) 107997
8
Psychopharmacology (Berlin) 94, 178–182. https://doi.org/10.1007/bf00176841.
PMID: 2965396.
Gregoire, L., Samadi, P., Graham, J., Bedard, P.J., Bartoszyk, G.D., Di Paolo, T., 2009.
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of
L-Dopa in parkinsonian monkeys. Park. Relat. Disord. 15, 445–452. https://doi.org/
10.1016/j.parkreldis.2008.11.001. PMID: 19196540.
Huot, P., 2018. 5-HT1A agonists and dyskinesia in Parkinson’s disease: a pharmacological
perspective. Neurodegener. Dis. Manag. 8, 207–209. https://doi.org/10.2217/nmt-
2018-0017. PMID: 30040029.
Huot, P., Johnston, T.H., Fox, S.H., Newman-Tancredi, A., Brotchie, J.M., 2015. The
highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia
without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
Neuropharmacology 97, 306–311. https://doi.org/10.1016/j.neuropharm.2015.05.
033. MID: 26071982.
Iderberg, H., McCreary, A.C., Varney, M.A., Cenci, M.A., Newman-Tancredi, A., 2015a.
Activity of serotonin 5-HT receptor ‘biased agonists’ in rat models of Parkinson’s
disease and l-DOPA-induced dyskinesia. Neuropharmacology 93C, 52–67. https://
doi.org/10.1016/j.neuropharm.2015.01.012. PMID: 25645393.
Iderberg, H., McCreary, A.C., Varney, M.A., Kleven, M.S., Koek, W., Bardin, L.,
Depoortère, R., Cenci, M.A., Newman-Tancredi, A., 2015b. NLX-112, a novel 5-HT1A
receptor agonist for the treatment of L-DOPA-induced dyskinesia: behavioral and
neurochemical profile in rat. Exp. Neurol. 271, 335–350. https://doi.org/10.1016/j.
expneurol.2015.05.021. PMID: 26037043.
Iravani, M.M., Tayarani-Binazir, K., Chu, W.B., Jackson, M.J., Jenner, P., 2006. In 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydro-
xytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia
but only with increased motor disability. J. Pharmacol. Exp. Therapeut. 319,
1225–1234. https://doi.org/10.1124/jpet.106.110429. PMID: 16959959.
Jackson, M.J., Al-Barghouthy, G., Pearce, R.K., Smith, L., Hagan, J.J., Jenner, P., 2004.
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function
in haloperidol and MPTP-treated common marmosets. Pharmacol. Biochem. Behav.
79, 391–400. https://doi.org/10.1016/j.pbb.2004.07.015. PMID: 15582011.
Jenner, P., McCreary, A.C., Scheller, D.K., 2011. Continuous drug delivery in early- and
late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and
expression. J. Neural. Transm. 118, 1691–1702. https://doi.org/10.1007/s00702-
011-0703-9. PMID: 21881838.
Levigoureux, E., Vidal, B., Bouillot, C., Billard, T., Newman-Tancredi, A., Zimmer, L.,
2019a. PET imaging of functional 5-HT1A receptors in hemiparkinsonian rats.
NeuroFrance 2019 Marseille, France, Poster P2.094.
Levigoureux, E., Vidal, B., Fieux, S., Bouillot, C., Emery, S., Newman-Tancredi, A.,
Zimmer, L., 2019b. Serotonin 5-HT1A receptor biased agonists induce different cer-
ebral metabolic responses: a [18F]FDG PET study in conscious and anesthetized rats.
ACS Chem. Neurosci. 10, 3108–3119. https://doi.org/10.1021/acschemneuro.
8b00584. PMID: 30576601.
Lindenbach, D., Palumbo, N., Ostock, C.Y., Vilceus, N., Conti, M.M., Bishop, C., 2015.
Side effect profile of 5-HT treatments for Parkinson’s disease and L-DOPA-induced
dyskinesia in rats. Br. J. Pharmacol. 172, 119–130. https://doi.org/10.1111/bph.
12894. PMID: 25175895.
Llado-Pelfort, L., Assie, M.B., Newman-Tancredi, A., Artigas, F., Celada, P., 2012. In vivo
electrophysiological and neurochemical effects of the selective 5-HT1A receptor
agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.
Psychopharmacology 221, 261–272. https://doi.org/10.1007/s00213-011-2569-9.
PMID: 22147258.
Matsubara, K., Shimizu, K., Suno, M., Ogawa, K., Awaya, T., Yamada, T., Noda, T.,
Satomi, M., Ohtaki, K., Chiba, K., Tasaki, Y., Shiono, H., 2006. Tandospirone, a 5-
HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats
with unilateral 6-hydroxydopamine-generated lesions. Brain Res. 1112, 126–133.
https://doi.org/10.1016/j.brainres.2006.07.003. PMID: 16884702.
McCreary, A.C., Varney, M.A., Newman-Tancredi, A., 2016a. The novel 5-HT1A receptor
agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: a
chronic administration study with microdialysis measurements. Neuropharmacology
105, 651–660. https://doi.org/10.1016/j.expneurol.2015.05.021. PMID: 26037043.
McCreary, A.C., Varney, M.A., Newman-Tancredi, A., 2016b. The novel 5-HT receptor
agonist, NLX-112 reduces L-DOPA-induced abnormal involuntary movements in rat:
a chronic administration study with microdialysis measurements.
Neuropharmacology 105, 651–660. https://doi.org/10.1016/j.neuropharm.2016.01.
013. PMID: 26777281.
Meadows, S.M., Chambers, N.E., Conti, M.M., Bossert, S.C., Tasber, C., Sheena, E.,
Varney, M., Newman-Tancredi, A., Bishop, C., 2017. Characterizing the differential
roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-in-
duced dyskinesia. Exp. Neurol. 292, 168–178. https://doi.org/10.1016/j.expneurol.
2017.03.013. PMID: 28342749.
Munoz, A., Li, Q., Gardoni, F., Marcello, E., Qin, C., Carlsson, T., Kirik, D., Di Luca, M.,
Bjorklund, A., Bezard, E., Carta, M., 2008. Combined 5-HT1A and 5-HT1B receptor
agonists for the treatment of L-DOPA-induced dyskinesia. Brain : J. Neurol. 131,
3380–3394. https://doi.org/10.1093/brain/awn235. PMID: 18952677.
Nair, A.B., Jacob, S., 2016. A simple practice guide for dose conversion between animals
and human. J. Basic Clin. Pharm. 7, 27–31. https://doi.org/10.4103/0976-0105.
177703. PMID: 27057123.
Newman-Tancredi, A., Bardin, L., Auclair, A., Colpaert, F., Depoortere, R., Varney, M.A.,
2018a. NLX-112, a highly selective 5-HT1A receptor agonist, mediates analgesia and
antidepressant-like activity in rats via spinal cord and prefrontal cortex 5-HT1A re-
ceptors, respectively. Brain Res. 1688, 1–7. https://doi.org/10.1016/j.brainres.2018.
03.016. PMID: 29555239.
Newman-Tancredi, A., Depoortere, R., Carilla-Durand, E., Tarayre, J.P., Kleven, M., Koek,
W., Bardin, L., Varney, M.A., 2018b. NLX-112, a highly selective 5-HT1A receptor
agonist: effects on body temperature and plasma corticosterone levels in rats.
Pharmacol. Biochem. Behav. 165, 56–62. https://doi.org/10.1016/j.pbb.2017.11.
002. PMID: 29126856.
Newman-Tancredi, A., Martel, J.C., Cosi, C., Heusler, P., Lestienne, F., Varney, M.A.,
Cussac, D., 2017. Distinctive in vitro signal transduction profile of NLX-112, a potent
and efficacious serotonin 5-HT1A receptor agonist. J. Pharm. Pharmacol. 69,
1178–1190. https://doi.org/10.1111/jphp.12762. PMID: 28612503.
Paillard, B.D.F.L., Brunner, V., Newman-Tancredi, A., Varney, M., 2016. A method for
treating movement disorders with befiradol. In: Pierre Fabre Medicament, WO2016/
005527A1.
Pearce, P.K., et al., 1995. Chronic L-DOPA administration induces dyskinesias in the 1-
methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix
Jacchus). Mov Disord 10 (6), 731–740 PMID: 8749992.
Peroutka, S.J., 1985. Selective interaction of novel anxiolytics with 5-
hydroxytryptamine1A receptors. Biol. Psychiatr. 20, 971–979. https://doi.org/10.
1016/0006-3223(85)90194-5. PMID: 2862927.
Pilleri, M., Antonini, A., 2015. Therapeutic strategies to prevent and manage dyskinesias
in Parkinson’s disease. Expet Opin. Drug Saf. 14, 281–294. https://doi.org/10.1517/
14740338. PMID: 25483147.
Politis, M., Wu, K., Loane, C., Brooks, D.J., Kiferle, L., Turkheimer, F.E., Bain, P., Molloy,
S., Piccini, P., 2014. Serotonergic mechanisms responsible for levodopa-induced
dyskinesias in Parkinson’s disease patients. J. Clin. Invest. 124, 1340–1349. https://
doi.org/10.1172/JCI71640. PMID: 24531549.
Prinssen, E.P., Koek, W., Colpaert, F.C., Kleven, M.S., 2000. Repeated treatment with 8-
OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syn-
drome, but not to its ability to attenuate haloperidol-induced catalepsy. Behav.
Pharmacol. 11, 299–305. https://doi.org/10.1097/00008877-200006000-00013.
PMID: 11103884.
Rabiner, E.A., Gunn, R.N., Wilkins, M.R., Sedman, E., Grasby, P.M., 2002. Evaluation of
EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with
[11C]WAY-100635 and [11C]raclopride. J. Psychopharmacol. 16, 195–199. https://
doi.org/10.1177/026988110201600301. PMID: 12236624.
Rana, A.Q., Kabir, A., Jesudasan, M., Siddiqui, I., Khondker, S., 2013. Pain in Parkinson’s
disease: analysis and literature review. Clin. Neurol. Neurosurg. 115, 2313–2317.
https://doi.org/10.1016/j.clineuro.2013.08.022. PMID: 24075714.
Rana, A.Q., Qureshi, A.R., Rahman, L., Jesudasan, A., Hafez, K.K., Rana, M.A., 2016.
Association of restless legs syndrome, pain, and mood disorders in Parkinson’s dis-
ease. Int. J. Neurosci. 126 (2), 116–120. https://doi.org/10.3109/00207454.2014.
994208. PMID: 25469455.
Roussakis, A.A., Politis, M., Towey, D., Piccini, P., 2016. Serotonin-to-dopamine trans-
porter ratios in Parkinson disease: relevance for dyskinesias. Neurology 86,
1152–1158. https://doi.org/10.1212/WNL.0000000000002494. PMID: 26920358.
Schapira, A.H., Bezard, E., Brotchie, J., Calon, F., Collingridge, G.L., Ferger, B., Hengerer,
B., Hirsch, E., Jenner, P., Le Novere, N., Obeso, J.A., Schwarzschild, M.A.,
Spampinato, U., Davidai, G., 2006. Novel pharmacological targets for the treatment
of Parkinson’s disease. Nat. Rev. Drug Discov. 5, 845–854. https://doi.org/10.1038/
nrd2087. PMID: 17016425.
Sellnow, R.C., Newman, J.H., Chambers, N., West, A.R., Steece-Collier, K., Sandoval, I.M.,
Benskey, M.J., Bishop, C., Manfredsson, F.P., 2019. Regulation of dopamine neuro-
transmission from serotonergic neurons by ectopic expression of the dopamine D2
autoreceptor blocks levodopa-induced dyskinesia. Acta Neuropathol Commun 7, 8.
https://doi.org/10.1186/s40478-018-0653-7. PMID: 30646956.
Smith, L.M., Peroutka, S.J., 1986. Differential effects of 5-hydroxytryptamine1a selective
drugs on the 5-HT behavioral syndrome. Pharmacol. Biochem. Behav. 24,
1513–1519. https://doi.org/10.1016/0091-3057(86)90477-6. PMID: 2942947.
Tronci, E., Lisci, C., Stancampiano, R., Fidalgo, C., Collu, M., Devoto, P., Carta, M., 2013.
5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat
Parkinson’s disease model. Neurobiol. Dis. 60, 108–114. https://doi.org/10.1016/j.
nbd.2013.08.01. PMID: 24004632.
Veyres, N., Hamadjida, A., Huot, P., 2018. Predictive value of parkinsonian primates in
pharmacologic studies: a comparison between the macaque, marmoset, and squirrel
monkey. J. Pharmacol. Exp. Therapeut. 365, 379–397. https://doi.org/10.1124/jpet.
117.247171. PMID: 29523699.
Vidal, B., Fieux, S., Colom, M., Billard, T., Bouillot, C., Barret, O., Constantinescu, C.,
Tamagnan, G., Newman-Tancredi, A., Zimmer, L., 2018. (18)F-F13640 preclinical
evaluation in rodent, cat and primate as a 5-HT1A receptor agonist for PET neuroi-
maging. Brain Struct. Funct. 223, 2973–2988. https://doi.org/10.1007/s00429-018-
1672-7. PMID: 29730825.
Vidal, B., Sebti, J., Verdurand, M., Fieux, S., Billard, T., Streichenberger, N., Troakes, C.,
Newman-Tancredi, A., Zimmer, L., 2016. Agonist and antagonist bind differently to
5-HT1A receptors during Alzheimer’s disease: a post-mortem study with PET radio-
pharmaceuticals. Neuropharmacology 109, 88–95. https://doi.org/10.1016/j.
neuropharm.2016.05.009. PMID: 27183968.
Yokoyama, C., Mawatari, A., Kawasaki, A., Takeda, C., Onoe, K., Doi, H., Newman-
Tancredi, A., Zimmer, L., Onoe, H., 2016. Marmoset serotonin 5-HT1A receptor
mapping with a biased agonist PET probe 18F-F13714: comparison with an antago-
nist tracer 18F-MPPF in Awake and anesthetized states. Int. J.
Neuropsychopharmacol. 19 (12), 1–12. https://doi.org/10.1093/ijnp/pyw079.
PMID: 27608810.
R. Fisher, et al. Neuropharmacology 167 (2020) 107997
9
